← All indications
Dissociative Disorders
Sudden temporary alterations in the normally integrative functions of consciousness.
Subtype terms (1)
More specific conditions that are subtypes of Dissociative Disorders in the MeSH hierarchy.
Drugs by status
Phase 4 trials (3)
Phase 2 trials (1)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (19)
- Regeneron
- Novartis
- Ocular Therapeutix, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Brown University
- Rhode Island Hospital
- Southern California Desert Retina Consultants, MC
- Stanford University
- University of Bern
- University of Bonn
- Tennessee Retina
- University of Cincinnati
- Rocky Vista University
- University of Munster
- University of Western Ontario
- American Epilepsy Society
- Epilepsy Foundation
- Midwest Eye Institute
- Midwest Medical Advisors, Inc
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (13)
- ISTA Pharmaceuticals
- Bausch & Lomb
- Merck
- Barnes Retina Institute
- Thomas Jefferson University
- University of Heidelberg
- University of California, Los Angeles
- University of Freiburg
- University of Sao Paulo
- Oncology Service, Wills Eye Institute
- University of Wisconsin
- Eye Associates of New Mexico
- Southeastern Retina Associates
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (5)